List of companies in Palo Santo Fund's investment portfolio

Delix Therapeutics is a CNS-focused drug discovery company.

Developer of a psychedelic therapy application designed to auto-generate soothing and individualized soundtracks for drug-free therapy. The company's application combines immersive media with advances in intelligent technologies and psychedelic science to develop mobile tools and physical spaces that re-connect with the user's inner resources.

Beckley Psytech is a psychedelic Compounds founded in 2019 by Lady Amanda Feilding.

Gilgamesh Pharmaceuticals is a pharmaceutical platform company developing an oral arylcyclohexylamine therapeutic and the next generation of psychedelic-related medicines.

Operator of drug discovery platform intended to develop novel FDA-approved psychoactive medicines. The company's platform leverages plant derived compounds to accelerate the development of novel therapeutics, enabling physicians with the treatment and prevention of psychiatric and neurological disorders.

London-based company developing anti-inflammatory treatments for Alzheimer's and other conditions using psychedelic compounds like LSD and peyote.

Developer of a digital mental health platform intended to improve mental health through objective measurement and personalized intervention. The company's platform offers scalable, passive, and continuous remote patient monitoring and digital therapeutics for behavioral health.

Developer of an online platform for psychotherapists designed to grow their practice with psychedelic therapy. The company provides independent licensed mental health practitioners and private psychotherapy practices the prescription services they need.

Fluence offers continuing education and certificate programs in psychedelic integration and psychedelic-assisted therapy.

Developer of a subcutaneous ketamine delivery system designed to address the limitations of current ketamine preparations to allow control of overdosing and reduced the need for monitoring.

Developer of novel therapies designed to treat common nervous system disorders. The company uses a novel, allosteric modulation approach to discover novel therapies that would bind at the 5HT receptors in the brain.p

Developer of novel therapeutics intended to discover new drugs based on biotechnological research. The company specializes in pre-clinical biotechnological research that focuses on the plant sceletium tortuosum which is a medicinal succulent traditionally used by the San hunter-gatherers of South Africa.